“Despite success with immune checkpoint inhibitors, clinical benefit from cancer vaccines remains elusive. Combined targeting of melanoma-specific CD4+ and CD8+ T-lymphocyte epitopes was associated with improved survival compared with targeting either alone, or when a nonspecific helper epitope was used. We discuss the potential role of antigen-specific CD4 help.”
CureVac, a German biopharmaceutical company, announced the start of a phase IIb clinical trial of its vaccine, CV9104, for castration-resistant prostate cancer (CRPC). The vaccine works by prompting the body’s own immune system to attack prostate cancer cells. The trial will enroll up to 200 patients across eight European countries who have never received chemotherapy for CRPC. For more information on the clinical trial click here.
“CureVac GmbH, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has initiated a double-blind, randomized Phase 2b clinical trial of its RNActive® cancer vaccine, CV9104, for the treatment of patients with castration-resistant prostate cancer.”
The pre-vaccination IgM antibodies to anti-BG-Atr were significantly associated with survival in patients with advanced prostate cancer treated with PROSTVAC-VF. This antibody may be a predictive biomarker for response to PROSTVAC-VF if validated.